Figure 2.

Hematopoietic-specific Tak1 deletion does not impair the development of splenocytes and circulating myeloid cells. (a) Gating strategy and representative flow cytometry data of control (no-Cre and Tak1-Het) and Tak1^HKO splenocytes at P0. (b) Total CD11b⁺ cells in P0 control (n=7) and Tak1^HKO (n=4) spleen as a percent of total live cells. (c) CD11b⁺ Ly6C^hi cells (monocytes) and (d) CD11b⁺ Ly6G⁺ cells (neutrophils) in P0 control (n=7) and Tak1^HKO (n=4) spleen as a percent of total live cells. (e) Gating strategy and representative flow cytometry data of control (no-Cre and Tak1-Het) and Tak1^HKO blood at P0. (f) Total CD11b⁺ cells in P0 control (n=8) and Tak1^HKO (n=5) blood as a percent of total live cells. (g) CD11b⁺ Ly6C^hi cells (monocytes) and (H) CD11b⁺ Ly6G⁺ cells (neutrophils) in P0 control (n=8) and Tak1^HKO (n=4) blood as a percent of total live cells. Means±S.E. and all data points are shown. *P<0.05; NS, not significant (two-tailed Student's t-test with equal distributions)